Patents Assigned to The Rockfeller University
  • Patent number: 11497797
    Abstract: Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.
    Type: Grant
    Filed: March 29, 2022
    Date of Patent: November 15, 2022
    Assignee: The Rockfeller University
    Inventors: David Bikard, Luciano Marraffini
  • Publication number: 20190274619
    Abstract: An optical system for the detection of skin disease, such as melanoma, acquires images of a lesion on a subject's skin at different wavelengths and utilizes a sweeping arm rotating about the lesion in a clock-like sweep to produce diagnostically relevant metrics and classifiers from the image data so as to enhance detection of the skin disease.
    Type: Application
    Filed: May 17, 2019
    Publication date: September 12, 2019
    Applicant: The Rockfeller University
    Inventors: Daniel GAREAU, Justin Martin
  • Patent number: 9005579
    Abstract: The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.
    Type: Grant
    Filed: January 5, 2011
    Date of Patent: April 14, 2015
    Assignees: Contrafect Corporation, The Rockfeller University
    Inventors: Robert C. Nowinski, Vincent A. Fischetti, Assaf Raz
  • Patent number: 7521241
    Abstract: A method is provided of regulating transcription in a plant cell from a DNA sequence comprising a target DNA operably linked to a coding sequence, which method comprises introducing an engineered zinc finger polypeptide in said plant cell which polypeptide binds to the target DNA and modulates transcription of the coding sequence.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: April 21, 2009
    Assignees: Gendaq Limited, The Rockfeller University
    Inventors: Yen Choo, Christopher Graeme Ullman, Nam-Hai Chua, Juan Pablo Sanchez
  • Patent number: 7432052
    Abstract: Compositions and methods for identifying and/or modulating RNA transcripts and/or genes involved in fragile X syndrome and other associated disorders are provided. In particular, RNA targets for fragile X mental retardation protein (FMRP) have been identified by a novel monoclonal antibody to FMRP and a consensus sequence for the RNA binding region has been identified. Arrays for identifying compounds, proteins, nucleotides, and the like that modulate the RNA targets or associated genes are provided. Additionally, methods for modulating RNA targets are provided.
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: October 7, 2008
    Assignees: The Rockfeller University, Duke University, Emory University
    Inventors: Stephen T. Warren, Victoria Brown-Kennerly, Peng Jin, Stephanie Ceman, Robert B. Darnell, Jennifer C. Darnell, Jack D. Keene, Scott A. Tenenbaum
  • Patent number: 7381705
    Abstract: The present invention relates to methods that employ peptides or peptide derivatives to inhibit hepatitis C virus infection. The present invention is based in part on the discovery that E2 envelope glycoprotein of hepatitis C virus has previously undescribed domains that are important for interactions with cellular or viral proteins that are necessary for early steps in HCV infection. The present invention provides peptides and methods of treatment and prophylaxis of diseases induced by hepatitis C virus and related viruses.
    Type: Grant
    Filed: September 26, 2005
    Date of Patent: June 3, 2008
    Assignees: The Administrators Of The Tulane Educational Fund, The Rockfeller University
    Inventors: Robert F. Garry, Jane A. McKeating
  • Patent number: 7339039
    Abstract: Receptor recognition factors exist that recognizes the specific cell receptor to which a specific ligand has been bound, and that may thereby signal and/or initiate the binding of the transcription factor to the DNA site. The receptor recognition factor is in one instance, a part of a transcription factor, and also may interact with other transcription factors to cause them to activate and travel to the nucleus for DNA binding. The receptor recognition factor appears to be second-messenger-independent in its activity, as overt perturbations in second messenger concentrations are of no effect. The concept of the invention is illustrated by the results of studies conducted With interferon (IFN)-stimulated gene transcription, and particularly, the activation caused by both IFN? and IFN?. Specific DNA and amino acid sequences for various human and murine receptor recognition factors are provided, as are polypeptide fragments of two of the ISGF-3 genes, and antibodies have also been prepared and tested.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: March 4, 2008
    Assignee: The Rockfeller University
    Inventors: James E. Darnell, Jr., Christian W. Schindler, Xin-Yuan Fu, Zilong Wen, Zhong Zhong
  • Patent number: 7033759
    Abstract: Provided herein are variant alleles of a gene encoding a kappa opioid receptor, along with cloning vectors for replicating such variant alleles, and expressing vectors for expressing the variant alleles to produce variant kappa opioid receptors.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: April 25, 2006
    Assignee: The Rockfeller University
    Inventors: Mary Jeanne Kreek, Vadim Yuferov, Karl Steven LaForge
  • Patent number: 6395482
    Abstract: Variations in the DNA sequence of the human proline dehydrogenase gene (PRODH) which correlate to an increased susceptibility to, or presence of schizophrenia or a disease or disorder related thereto, such as obsessive compulsive disorder (OCD), bipolar disorder (BP), or major depressive disorder (MDD) are provided, along with assays to diagnosing schizophrenia or a disease or disorder related thereto, and evaluating potential drugs or agents for using in treating such diseases or disorders.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: May 28, 2002
    Assignee: The Rockfeller University
    Inventors: Maria Karayiorgou, Joseph A. Gogos
  • Patent number: 6369030
    Abstract: Histone acetyltransferase inhibitors, especially those that are differentiate between p300 and PCAF histone acetyltransferase; also therapeutic processes comprising their administration to humans.
    Type: Grant
    Filed: November 29, 1999
    Date of Patent: April 9, 2002
    Assignee: The Rockfeller University
    Inventors: Philip A. Cole, Raymond E. Soccio, Ontario D. Lau, Ehab M. Khalil, Tapas K. Kundu, Robert G. Roeder
  • Patent number: 6346605
    Abstract: A novel component of the TRAF (TNF Receptor Associated Factor) signaling complex, designated TRIP (TRAF Interacting Protein) which associates with the TNFR2 or CD30 signaling complex through its interaction with the TRAF2 protein and influences signals responsible for cell activation, cell proliferation and cell death.
    Type: Grant
    Filed: March 31, 1998
    Date of Patent: February 12, 2002
    Assignee: The Rockfeller University
    Inventors: Soo Young Lee, Yongwon Choi
  • Patent number: 6309853
    Abstract: The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of body weight, and to diagnostic and therapeutic uses of such modulators. In its broadest aspect, the present invention relates to nucleotide sequences corresponding to the murine and human OB gene, and two isoforms thereof, and proteins expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight and that have been postulated to play a critical role in the regulation of body weight and adiposity. The present invention further provides nucleic acid molecules for use as molecular probes or as primers for polymerase chain reaction (PCR) amplification. In further aspects, the present invention provides cloning vectors and mammalian expression vectors comprising the nucleic acid molecules of the invention.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 30, 2001
    Assignee: The Rockfeller University
    Inventors: Jeffrey M. Friedman, Yiying Zhang, Ricardo Proenca
  • Patent number: 6297356
    Abstract: The present invention relates to a novel nucleotide sequence encoding a telomeric protein which binds a repeat region of telomeric sequences, and to the protein encoded thereby. Also included within the invention are expression vectors for the production of the telomeric protein and host cells transformed with the nucleotide sequence. In addition, antibodies, probes and antagonists specific for the telomeric protein are contemplated. Methods of identifying antagonists of the telomeric protein, diagnostic methods of identifying the telomeric protein in a sample, and therapeutic uses of the telomeric protein, particularly in the treatment of aging and cancer, are also contemplated.
    Type: Grant
    Filed: February 4, 1998
    Date of Patent: October 2, 2001
    Assignee: The Rockfeller University
    Inventors: Titia DeLange, Dominique Broccoli, Agata Smogorzenska
  • Patent number: 6291428
    Abstract: Peptides are provided with the properties of enhancing the migration and adhesion of bone-forming cells to a substrate, useful for promoting bone mineralization and osseointegration in the healing of, for example, orthopedic surgical procedures.
    Type: Grant
    Filed: December 20, 1999
    Date of Patent: September 18, 2001
    Assignees: The Hospital for Special Surgery, The Rockfeller University
    Inventors: William B. Macaulay, Elizabeth Merrifield, Adele Boskey
  • Patent number: 6143566
    Abstract: A simple method for modifying genes in a recombination deficient host cell is disclosed. Such modifications include generating insertion, deletions, substitutions, and/or point mutations at any chosen site in the independent origin based cloning vector. The modified gene can be contained in an independent origin based cloning vector that is used to introduce a modified heterologous gene into a cell. Such a modified vector may be used in the production of a germline transmitted transgenic animal, or in gene targeting protocols in eukaryotic cells.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: November 7, 2000
    Assignee: The Rockfeller University
    Inventors: Nathaniel Heintz, Peter Model, Xiangdong W. Yang
  • Patent number: 6139831
    Abstract: Apparatus and method for immobilizing molecules, particularly biomolecules such as DNA, RNA, proteins, lipids, carbohydrates, or hormones onto a substrate such as glass or silica; patterns of immobilization can be made resulting in addressable, discrete arrays of molecules on a substrate, having applications in bioelectronics, DNA hybridization assays, drug assays, etc.
    Type: Grant
    Filed: May 28, 1998
    Date of Patent: October 31, 2000
    Assignee: The Rockfeller University
    Inventors: Ganaganor Visweswara Shivashankar, Albert J. Libchaber
  • Patent number: 6124448
    Abstract: The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of weight, and to the diagnostic and therapeutic uses to which such modulators may be put. In its broadest aspect, the present invention relates to the elucidation and discovery of nucleotide sequences, and proteins putatively expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight. The nucleotide sequences in object represent the genes corresponding to the murine and human ob gene, that have been postulated to play a critical role in the regulation of body weight and adiposity. Preliminary data, presented herein, suggests that the polypeptide product of the gene in question functions as a hormone.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 26, 2000
    Assignee: The Rockfeller University
    Inventors: Jeffrey M. Friedman, Yiying Zhang, Ricardo Proenca, Margherita Maffei
  • Patent number: 6124118
    Abstract: Receptor recognition factors exist that recognizes the specific cell receptor to which a specific ligand has been bound, and that may thereby signal and/or initiate the binding of the transcription factor to the DNA site. The receptor recognition factor is in one instance, a part of a transcription factor, and also may interact with other transcription factors to cause them to activate and travel to the nucleus for DNA binding. The receptor recognition factor appears to be second-messenger-independent in its activity, as overt perturbations in second messenger concentrations are of no effect. The concept of the invention is illustrated by the results of studies conducted with interferon (IFN)-stimulated gene transcription, and particularly, the activation caused by both IFN.alpha. and IFN.gamma..
    Type: Grant
    Filed: October 10, 1997
    Date of Patent: September 26, 2000
    Assignee: The Rockfeller University
    Inventors: James E. Darnell, Jr., Christian W. Schindler, Xin-Yuan Fu, Zilong Wen, Zhong Zhong
  • Patent number: 6106844
    Abstract: The present invention is directed to immunogenic peptides from vespid antigen 5. These immunogenic peptides can be used in immunotherapy for vespid venom allergic individuals. The present invention is thus directed to T cell epitopes of vespid antigen 5 that can anergize T cell responses in sensitive individuals.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: August 22, 2000
    Assignee: The Rockfeller University
    Inventor: Te Piao King
  • Patent number: 6057129
    Abstract: The present invention provides isolated nucleic acids and/or recombinant DNA molecules that encode the clock protein DOUBLETIME. The present invention further provides both isolated and/or recombinant DOUBLETIME. In addition, the present invention provides antibodies to DOUBLETIME. Methods of using the nucleic acids, proteins and antibodies of the present invention, including as therapeutics are also provided.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: May 2, 2000
    Assignee: The Rockfeller University
    Inventors: Michael W. Young, Brian Kloss, Justin Blau, Jeffrey Price